Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
EGenesis
company
About
EGenesis focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs.
- 1 - 10
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $100M
- Industries
- Biopharma,Biotechnology,Genetics,Life Science,Medical
- Founded date
- Jan 1, 2014
- Number Of Employee
- 1 - 10
- Operating Status
- Active
EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$263M
EGenesis has raised a total of
$263M
in funding over 2 rounds. Their latest funding was raised on
Mar 2, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 2, 2021 | Series C | $125M | 1 | — | — | Detail |
| Nov 7, 2019 | Series B | $100M | 2 | — | — | Detail |
| Mar 16, 2017 | Series A | $38M | 2 |
ARCH Venture Partners
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
EGenesis is funded by 3 investors.
ARCH Venture Partners
and Bayer
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
ARCH Venture Partners
|
— | Series C |
Bayer
|
— | Series B |
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
